Status:
COMPLETED
Combination Bevacizumab and Verteporfin (Two Different Sequences of Treatment)in Neovascular AMD
Lead Sponsor:
Retinal Consultants Medical Group
Conditions:
Choroidal Neovascularization
Macular Degeneration
Eligibility:
All Genders
55+ years
Phase:
PHASE2
Brief Summary
The purpose of this research study is to compare different timing therapies of Verteporfin with Bevacizumab to treat choroidal neovascularization (CNV) due to age-related macular degeneration (AMD).
Eligibility Criteria
Inclusion
- Patients are men or women of age 55 or older
- Patients have subfoveal CNV due to AMD with lesion size less than or equal to 9 MPS DA
- patients have not received previous treatment for subfoveal CNV due to AMD.
- Patients have a visual acuity between 20/40 and 20/320-
Exclusion
- Subjects who have received previous treatment for subfoveal CNV, in their study eye including prior PDT, transpupillary thermotherapy (TTT), submacular surgery, drug therapies such as Macugen or other anti-angiogenic compounds, or other local treatment. Previous laser photocoagulation therapy is acceptable, provided it was not subfoveal.
- Patients with a known hypersensitivity/allergy to verteporfin, porfimer sodium, or other porphyrins, porphyria or other porphyrin sensitivity, or hypersensitivity to sunlight or bright artificial light.
- Patients who use medications that may induce photosensitivity.
- Patients who have undergone YAG capsulotomy within the last month.
- Subjects currently involved in any experimental procedure within the last 12 weeks.
- Female patients who are pregnant, fecund or breast-feeding.
- \-
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00426998
Start Date
April 1 2006
Last Update
January 26 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Retinal Consultants Medical Group, Inc.
Sacramento, California, United States, 95819